Search hospitals > Colorado > Pueblo
Saint Mary Corwin Medical Center
Claim this profilePueblo, Colorado 81004
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
343 reported clinical trials
3 medical researchers
Summary
Saint Mary Corwin Medical Center is a medical facility located in Pueblo, Colorado. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Saint Mary Corwin Medical Center is involved with conducting 343 clinical trials across 457 conditions. There are 3 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, and Mehmet S. Copur.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Richard L. DemingMercy Medical Center - Des Moines4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
170 reported clinical trials
235 drugs studied
Shahzad SiddiquePenrose-Saint Francis Healthcare4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
100 reported clinical trials
168 drugs studied
Mehmet S. CopurRocky Mountain Cancer Centers-Thornton12 years of reported clinical research
Studies Ovarian Cancer
Studies Peritoneal Serous Adenocarcinoma
2 reported clinical trials
8 drugs studied
Clinical Trials running at Saint Mary Corwin Medical Center
Breast Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Bladder Carcinoma
Prostate Cancer
Pancreatic Cancer
Multiple Myeloma
Adenocarcinoma
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Saint Mary Corwin Medical Center?
Saint Mary Corwin Medical Center is a medical facility located in Pueblo, Colorado. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Saint Mary Corwin Medical Center is involved with conducting 343 clinical trials across 457 conditions. There are 3 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, and Mehmet S. Copur.
Where is Saint Mary Corwin Medical Center located?
St. Mary-Corwin Medical Center is located at 1008 Minnequa Avenue, Pueblo, CO 81004. To reach the hospital from I-25, take exit 101A for US-50 W toward Pueblo. Continue on US-50 W, turn right onto W 29th Street, left onto N Grand Avenue, right onto W 16th Street, and continue onto Minnequa Avenue; the hospital will be on your left.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Saint Mary Corwin Medical Center, contact (844) 853-7359. Office hours are 8:30 a.m. to 11 p.m. on weekdays, and 11 a.m. to 11 p.m. on weekends. Applications for financial assistance are available in English and Spanish; for other languages or to obtain written copies, contact a financial counselor or email billing@stmarysathens.org.
What insurance does Saint Mary Corwin Medical Center accept?
Saint Mary Corwin Medical Center, a Centura Health facility, accepts a range of insurance plans including Anthem, Cigna, Rocky Mountain, and Kaiser Permanente. Additionally, Allina Health, which operates Corwin, accepts original Medicare, most Medicare Advantage and Private-Fee-For-Service plans, Medicaid, MinnesotaCare, and select health insurance exchange plans in Minnesota and Wisconsin. It is recommended to verify insurance acceptance directly with the hospital or provider.
What awards or recognition has Saint Mary Corwin Medical Center received?
Saint Mary Corwin Medical Center, located in Pueblo, Colorado, is accredited by the Commission on Cancer (CoC), signifying its commitment to providing high-quality cancer care. The hospital is also recognized for its active participation in clinical trials through Policy Lab.